bispecific monoclonal antibodies and car t-cell therapy in multiple myeloma, omar nadeem, md
Published 2 years ago • 2.1K plays • Length 19:37Download video MP4
Download video MP3
Similar videos
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
7:15
evolving myeloma treatment options | bispecific antibody therapy
-
31:00
car t-cells multiple myeloma: adam sperling, md, phd
-
0:39
car-t, bispecifics and mrd: how is treatment for multiple myeloma evolving?
-
28:40
bispecific antibody therapy in multiple myeloma
-
4:28
evolving myeloma treatment options | car t-cell therapy
-
1:27
the value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
30:43
evolving myeloma treatment options: how you can access cutting-edge care
-
22:48
car t cells in multiple myeloma
-
1:37
blood cancer research: car-t in multiple myeloma
-
2:27
bms-986393, a novel anti-gprc5d car-t cell therapy, in multiple myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
3:13
next generation myeloma treatment options
-
0:25
how bispecific antibodies work
-
36:17
update on multiple myeloma treatment: kenneth c. anderson, md
-
2:31
what are currently available myeloma treatments?
-
4:45
bispecifics part 2: monoclonal and bispecific antibodies
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma